Mirum Pharmaceuticals, Inc. — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On September 28, 2026, Mirum Pharmaceuticals executed a Transition and Separation Agreement with Joanne Quan, MD, setting her separation date at October 19, 2026. Severance includes: 9 months base salary, 12-month equity acceleration, $38,953.27 COBRA payment, full target annual bonus (100% achievement), and 12-month post-termination exercise period extension. No specific salary or bonus amounts are disclosed in the filing; Quan signed the Updated Release on October 22, 2026, making severance effective eight days later.
Why this rating
Single mid-level executive departure with standard severance. No disclosed cash amount, equity value, or role details. Routine personnel action immaterial to $2.3B market-cap company.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.